Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Addus HomeCare

Integer Holdings

Owens & Minor

Progyny

CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.

Jim Cramer recommends five small-cap health-care stocks

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

Axsome Therapeutics

Krystal Biotech

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Centessa Pharmaceuticals PLC

Cytokinetics

Iovance Biotherapeutics

Madrigal Pharmaceuticals

Bio-Techne

Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.

7 Biotech Stocks Ready to Ride the Sector's Resurgence

Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in the United States (U.S.) by Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), the Company's commercialization partner for North America.

Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

ACM Research

Alphatec Hlds

If you want big returns, you gotta think small – as in small-cap stocks. That's not to say the large-capitalization enterprises can't get you to investment Valhalla.

3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio

COMPASS Pathways

Vertex Pharmaceuticals

Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Barclays 26th Annual Global Healthcare Conference being held in Miami on March 12-14, 2024.

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.22 per share a year ago.

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Diluted Reported 2023 Non-GAAP Net Income of $223.2 Million, $1.96 Per Share Diluted Bolstered Neuroscience Commercial Portfolio with the FDA Approval of AGAMREE® Commercial Launch of AGAMREE on Track for Q1 2024 Full Year 2024 Total Revenues Guidance of Between $455 Million and $475 Million Conference Call and Webcast to be Held on February 29, 2024, at 8:30 AM ET CORAL GABLES, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2023 and provided a business update.

Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases, today announced an upcoming poster about the establishment of a registry to study long-term safety and quality of life (QoL) in patients with Duchenne muscular dystrophy (DMD) who are treated with AGAMREE® (vamorolone) at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of Vamorolone Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of Vamorolone

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on February 29, 2024, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Volitionrx Limited

Estrella Immunopharma Inc

The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

Caribou Biosciences

Recursion Pharmaceuticals

Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.

3 Biotech Stocks You Can Buy and Hold for the Next Decade

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

Amprius Technologies Inc

Immunocore Holdings

IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.

Best Momentum Stocks to Buy for January 10th

Eastman Chemical

Gigacloud Tech

Ramaco Resources

SkyWest

Consider investing in high-yield value stocks like GCT, SKYW, METC, EMN and CPRX to unlock your portfolio's potential.

5 Value Stocks With Strong Earnings Yield to Rev Up Returns

EnerSys

Panasonic Holdings Corp

PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.

News for Catalyst Pharmaceuticals Stock (CPRX)